Drug Trial Radar · NCT06072326
dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Jan 2027
Primary completion
Jan 2029
Study completion Jan 2030
Sponsor
- Lead sponsor
- University Medical Center GroningenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Juvenile Diabetes Research Foundation; Biocity Biopharmaceutics Co., Ltd.
- First posted
- Oct 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to test the hypothesis that dapagliflozin (SGLT2 inhibitor) and SC0062 (ERA) combination therapy augments nephroprotection and mitigates fluid retention and ketogenesis in people with T1D through complementary and synergistic mechanisms of actions.
Conditions
- Type 1 Diabetes Mellitus With Diabetic Nephropathy
Interventions
Dapagliflozin (Forxiga®)Drug
5 mg/day as a tablet
SC0062 strength 10mgDrug
20 mg/day, once daily, 2 capsules of 10 mg
SC0062 and dapagliflozinDrug
20 mg/day, once daily, 2 capsules of 10 mg, in combination with 5 mg/day dapagliflozin 5 mg as a tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Urine Albumin-Creatinine Ratio (UACR)Time frame: From randomization to end of study (V10) up to approximately 24 weeks
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
Steno Diabetes Center Aarhus
Aarhus, Denmark
Steno Diabetes Center Copenhagen
Copenhagen, Denmark
Regionshospitalet Gødstrup
Herning, Denmark
Turku University Hospital
Turku, Finland
University of Helsinki
Helsinki, Uusimaa, Finland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.